

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/108465/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Taylor, Michael ORCID: <https://orcid.org/0000-0003-1351-939X> and Hughes, Simon M. 2017. Mef2 and the skeletal muscle differentiation program. Seminars in Cell and Developmental Biology 72 , pp. 33-44. 10.1016/j.semcdb.2017.11.020 file

Publishers page: <https://doi.org/10.1016/j.semcdb.2017.11.020>
<<https://doi.org/10.1016/j.semcdb.2017.11.020>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Mef2 and the skeletal muscle differentiation program

Michael V. Taylor¹ and Simon M. Hughes²

1. School of Biosciences, Sir Martin Evans Building, Cardiff University, Museum Avenue, Cardiff CF10 3AX, UK.
2. Randall Division of Cell and Molecular Biophysics, New Hunt's House, Guy's Campus, King's College London, London SE1 1UL, UK.

Abstract

Mef2 is a conserved and significant transcription factor in the control of muscle gene expression. In cell culture Mef2 synergises with MyoD-family members in the activation of gene expression and in the conversion of fibroblasts into myoblasts. Amongst its *in vivo* roles, Mef2 is required for both *Drosophila* muscle development and mammalian muscle regeneration. Mef2 has functions in other cell-types too, but this review focuses on skeletal muscle and surveys key findings on Mef2 from its discovery, shortly after that of MyoD, up to the present day. In particular, *in vivo* functions, underpinning mechanisms and areas of uncertainty are highlighted. We describe how Mef2 sits at a nexus in the gene expression network that controls the muscle differentiation program, and how Mef2 activity must be regulated in time and space to orchestrate specific outputs within the different aspects of muscle development. A theme that emerges is that there is much to be learnt about the different Mef2 proteins (from different paralogous genes, spliced transcripts and species) and how the activity of these proteins is controlled.

Keywords

Skeletal muscle development, Mef2, gene expression network, differentiation, regeneration, alternative splicing, protein interactions

Contents

1. Discovery of the conserved Mef2 family
2. Mef2 gene expression
3. What does Mef2 do in muscle?
 - 3.1 Mammalian cell culture
 - 3.2 Mef2 function in *Drosophila*
 - 3.3 Function of zebrafish Mef2
 - 3.4 Function of mouse Mef2
 - 3.5 Potential functions in muscle-related tissues
 - 3.6 Mef2 in muscle regeneration
 - 3.7 Mef2 and muscle fibre character
4. Mechanism of Mef2 action: Transcriptional targets and networks

- 4.1 Mef2 target genes in the context of development
 - 4.1.1 Number of Mef2 target genes
 - 4.1.2 Types of Mef2 target genes
 - 4.1.3 Mef2 target gene specificity
- 4.2 Vertebrate genomic studies and the emerging gene expression network
- 4.3 Downstream of Mef2: feedback and feed-forward
- 4.4 Closing the loop: Regulation of Mef2 expression
- 4.5 Network features
- 5. Mechanism of Mef2 action: post-transcriptional events
 - 5.1 Alternative splicing
 - 5.2 Mef2 modification
 - 5.3 Mef2 protein interactions
- 6. Coda: Conclusions and future directions
- Acknowledgement
- References

1. Discovery of the conserved Mef2 family

We write on the thirtieth anniversary of the publication of the paper describing the discovery of MyoD and its ability to transform a fibroblast into a myoblast ([1] Lassar, this special issue). It is difficult to overstate the impact of this discovery both to the field of muscle differentiation and also beyond, to cell differentiation programs in general and to cellular reprogramming. In mammals, MyoD was quickly identified as one of four structurally and functionally related transcription factors, the Myogenic Regulatory Factors (MRFs)[2]. They bind to specific DNA sequences found in the *cis*-regulatory modules (CRMs) that control the expression of many muscle genes, and together the MRFs have a critical role in muscle differentiation during animal development [3]. However, there is more to making muscle than the MRFs. For example, other DNA sequences in CRMs together with their cognate transcription factors are required for muscle gene expression. Indeed, MRFs can induce gene expression through DNA sequences that do not contain their binding site [4, 5]. Mef2 quickly emerged as another significant player in the transcription of muscle genes.

Mef2 was first identified using mammalian cultured cells [6]. It was described as a protein activity that bound to a DNA sequence, distinct from the MRF-binding site, found in a CRM of the muscle creatine kinase (MCK) gene that is responsible for the expression of MCK during muscle cell differentiation. This Mef2-binding DNA sequence was subsequently found to be in the CRMs of nearly every known muscle-specific gene [5, 7]. Molecular cloning of Mef2 [8, 9] revealed that Mef2 is a member of the evolutionarily ancient MADS family of transcription factors [10, 11]. This family also contains SRF, which itself has a role in the regulation of muscle gene expression [12] and references cited therein; [13].

Mef2 is highly conserved (Fig. 1). There are single *Mef2* genes in *Drosophila*, *C. elegans* and sea urchins, for example [7]. In contrast in the vertebrate genome, as with the MyoD family of MRFs, there are four closely-related *Mef2* genes: *Mef2a*, *-b*, *-c* and *-d* [7]. Different transcripts are generated from each gene by alternative splicing [7, 9] (see 5.1 for functional significance). The encoded proteins bind DNA with the

consensus sequence CTA(A/T)₄TAG and can form both homo- and hetero-dimers [8]. It is unknown whether different Mef2 isoforms bind to variants of the Mef2 consensus sequence [14]. Key functional domains include the N-terminal MADS box and the adjacent Mef2 domain, that together are necessary and sufficient for DNA-binding and dimerisation, and these regions show extensive sequence similarity across all the Mef2 proteins from different species [7]. Point mutations in the conserved MADS box of *Drosophila* Mef2 result in lethality [15]. The C-terminal region is required for transcriptional activation [16], but the sequence has diverged considerably in different Mef2 proteins. Mef2 protein bends DNA on high affinity binding [17], and while the MADS box confers DNA-binding specificity [8], the Mef2 domain modulates the DNA-binding affinity [16]. Both crystal and solution structures for a homodimerised highly conserved MADS/Mef2 domain of MEF2A bound to DNA have been determined [18-20]. Many aspects of the Mef2 structure/function relationship remain to be analysed.

2. Mef2 gene expression

An initial step in the investigation of the possible role of *Mef2* in muscle differentiation was to determine its pattern of expression during embryonic development. Moreover, the expression pattern of individual genes, and indeed isoforms of each gene, continues to aid the interpretation of phenotypes and yield insights into the role of individual gene products. We will focus on Mef2 in skeletal muscle although, and in contrast to the skeletal muscle-specific MRFs, Mef2s are expressed and function in cardiac and smooth muscle, endothelium, brain neurons and many other tissues [21].

Invertebrates have a single *Mef2* gene. In *Drosophila*, *Mef2* is initially expressed throughout the mesoderm at gastrulation and subsequently almost exclusively in muscle. Both progenitors and differentiated cells of the somatic muscle (the equivalent of vertebrate skeletal muscle), heart and visceral muscle express *Mef2* [22]. The situation is more complex in vertebrate species with their separate *Mef2a*, -*b*, -*c* and -*d* genes. Mouse was the first species in which their expression patterns were described during development.

Murine *Mef2* genes are expressed at significant levels in a wide variety of tissues, but several show highest expression in muscle. *Mef2c* mRNA was first detected in the developing heart and shortly after in somitic muscle, and remained abundant in developing skeletal muscle at e14.5, being particularly concentrated at points of muscle attachment [23, 24]. *Mef2d* showed a similar although weaker pattern in somitic muscle [23]. *Mef2a* is also highly expressed in somites containing differentiated muscle fibres [23]. *Mef2b* has the most divergent structure, the least obvious muscle-related expression and the least evidence for involvement in muscle development. The expression pattern of the *Mef2* genes during limb and head myogenesis is, to our knowledge, poorly described.

A striking feature of chick Mef2 expression is that it is biphasic. *Mef2b* and *Mef2c* show broad transient expression in nascent neck somites, prior to MRF expression [25]. In contrast later, in nascent trunk somites, *Mef2c* mRNA accumulates strongly prior to other Mef2 mRNAs in regions where both Myf5 and MyoD have become detectable [25]. *Mef2d* and *Mef2a* mRNAs are detected in each somite, a few hours after *Mef2c* [25, 26]. At slightly later stages, when terminally differentiated fibres are present in significant numbers in somites, the location of *Mef2c* and *Mef2d* mRNAs appear distinct, with *Mef2c* mRNA located at the dermomyotomal lips where new myogenesis is on-going and *Mef2d* mRNA located centrally within the myotome where more mature fibres are located [25]. Thus, *Mef2c* and *Mef2d* display a spatial and

temporal succession. This description reveals potentially interesting relationships both between the different Mef2 genes and to the MRFs, but the functional significance of this expression is at present unknown.

Zebrafish have six Mef2 genes, both *mef2a* and *mef2c* have two versions, and several are expressed during skeletal myogenesis [27]. Zebrafish *mef2d* is the first Mef2 gene detectably expressed, closely following the initiation of MRF expression in several distinct muscle precursor cell populations [28, 29]. *Mef2ca* mRNA accumulates later, in parallel with myosin expression, in several distinct myocyte populations as each begins to elongate and assemble myofibrils [29]. *mef2aa* and *mef2cb* are expressed in skeletal muscle after *mef2d* [30-36], but are not fully described. Expression patterns of *mef2b* and *mef2ab* have not been described, although neither was detected in somitic muscle at 2 days of age [35]. Mef2 immunoreactivity is particularly abundant in striated muscle [27, 29, 37-40]. Overall, it is clear that at least four Mef2 genes are sequentially expressed at high level during terminal differentiation of skeletal muscle in teleost fish.

Taken together, these studies show prominent and regulated expression of Mef2 genes during muscle development in a range of species. However, a lack of consensus across species in the order and location of expression of the four vertebrate Mef2 genes suggests that either underlying common patterns have been missed, or that gene usage has changed during evolution. Future studies at higher spatial and temporal resolution may resolve precisely when and where each Mef2 protein is available to function.

3. What does Mef2 do in muscle?

The prominent position of Mef2 in the field of muscle differentiation derives both from two early findings in mammalian cell culture and during development of *Drosophila melanogaster*, and from later work in a variety of model systems.

3.1 Mammalian cell culture

The first of these influential early studies uncovered a functional interaction between Mef2 proteins and MRFs [41]. The characteristic and striking property of the MRFs is that they can convert fibroblasts into myoblasts. This ability is greatly enhanced when MRFs are co-transfected with Mef2 [41]. Specifically, MyoD synergised with each of Mef2a, Mef2c and Mef2d, and Myogenin with Mef2c. Members of these two families of transcription factors also synergistically activated reporter gene expression [41]. This functional cooperation required direct physical interaction between the DNA-binding domains of both Mef2 and the MRF. Strikingly, it could occur through multiple copies of the binding sites for either Mef2 or MRF in the reporter construct. The study indicated that the two proteins could activate gene expression in two ways: (1) through binding to separate DNA sites; or (2) at a single site through a proposed Mef2/MRF physical interaction. Although muscle gene CRMs often contain nearby sites for the two factors [7, 42-45], the latter finding means that either factor could also activate transcription through the other's binding site. This offers an explanation for how MRFs can induce muscle gene expression through DNA sequences that do not contain an MRF-binding site [4, 5].

Mutational analyses of MRFs had revealed that an alanine and a threonine in their DNA-binding domain are required for muscle gene activation [46, 47]. However, these amino acids are not required for DNA-binding, and so it was proposed that they are necessary for an interaction with a co-regulatory factor

required for muscle gene activation. Strikingly, the synergistic interaction between Mef2 and MRFs in both myogenic conversion of fibroblasts and expression of reporter genes requires these two specific amino acids, suggesting that Mef2 factors are the proposed co-regulators for the MRFs [41]. However, definitive *in vivo* evidence for such direct interactions is still lacking.

This research was complemented by a loss-of-function study that used a 'dominant negative' Mef2 construct to show that Mef2 family function is required by MRFs for the myogenic conversion of fibroblasts [48]. The same construct also inhibits formation of myotubes from C2C12 myoblasts. More recently, an alternative approach of knocking down Mef2a expression using a *Mef2a*-specific shRNA also impaired C2C12 myotube formation [49]. Together these cell culture studies point to an intriguing function of *Mef2*, but it was critical to probe the role of *Mef2* in the much more complex *in vivo* situation, i.e. during the muscle differentiation program of gene expression in animal development. However, such analyses in vertebrates have been complicated by the aforementioned four closely-related Mef2 genes, with their overlapping expression patterns in multiple tissues.

3.2 *Mef2* function in *Drosophila*

The second influential early finding came from the analysis of *Mef2* function in *Drosophila*. Its single *Mef2* gene encodes a highly conserved MADS/Mef2 domain and is also alternatively spliced, in common with other species [50](Fig. 1). With the efficient genetics available, *Drosophila* was used to show that *Mef2* is required for muscle development during embryogenesis. *Mef2* mutant embryos lack differentiated somatic muscle [22, 51, 52]. Although somatic muscle progenitor cells are produced in a substantially unaffected pattern, they fail to fuse and differentiate further. The dominant conclusion from this period of Mef2 research was that it affects myogenesis relatively late, during the overt differentiation phase. We will return to this point in Section 4.1. Although the focus of this review is on skeletal muscle, it is of interest that *Mef2* is also required for proper differentiation of both the heart and visceral muscle, and again early steps in their development appear substantially unaffected. Thus, *Drosophila Mef2* is required for the differentiation of all the major muscle-types. As many muscle genes are expressed in multiple muscle-types, it is noteworthy that Mef2 might regulate some of the same genes in each, something that the MRFs cannot do.

There are two phases of myogenesis in *Drosophila* and *Mef2* is required for each. The first phase produces the larval musculature during embryogenesis, and the second produces the adult musculature during metamorphosis. *Drosophila* adult somatic muscles are physiologically and functionally diverse and, unlike the larva, some contain multiple fibres, characteristics that are in common with vertebrate skeletal muscles [53-56]. The largest muscles include the dorso-longitudinal indirect flight muscles (DLMs). The *Mef2* mutants used to establish a function in the first phase of myogenesis are embryonic lethal, but other *Mef2* hypomorphic mutants were found to have a reduced number of abnormally patterned DLMs [15, 57, 58]. More recently, temporally and spatially controlled expression of RNAi to knock-down *Mef2* function only in adult myogenesis has shown that *Mef2* is required for a diverse range of adult muscle types, including the DLMs and also the structurally distinct jump and leg muscles [59, 60]. DLMs are formed by a type of regeneration in a remodelling process during metamorphosis. Early in pupation, template larval muscles fuse with muscle progenitor cells that are maintained in an undifferentiated state in the larva. In early pupae in the RNAi *Mef2* loss-of-function condition, unfused myoblasts are found around the muscle templates, remodelling is inhibited, and at the end of pupation DLMs are completely absent. Of note, *Mef2* functions at

several distinct times in this muscle differentiation program (see 4.1). Temperature sensitive control of the *Mef2* RNAi expression showed that *Mef2* is required first for normal remodelling and then subsequently in promoting muscle maintenance [59]. Remodelling and maintenance are important aspects of tissue biology, and the functions for *Mef2* in these processes may have implications for muscle repair.

3.3 Function of zebrafish *Mef2*

Mef2 gene function in zebrafish skeletal muscle has been examined by a combination of loss- and gain-of-function analyses. With the exception of *mef2ca* mutants, which show delayed cardiomyogenesis and reduced somitic myotome volume and muscle fibre size, strong skeletal muscle phenotypes of single *Mef2* gene mutants or antisense morpholino knockdowns have not been reported [29, 33-35]. *Mef2ca;mef2cb* double mutants have a severe lack of cardiomyogenesis, but no additional defect in skeletal myogenesis was described [34]. Nevertheless, knockdown of several *Mef2* proteins with either a single broad-spectrum anti-*Mef2* morpholino or a combination of *mef2ca* loss-of-function mutation with a specific *Mef2d* morpholino yielded a failure of proper sarcomere assembly and reduction in mRNA levels for a variety of sarcomeric proteins [29]. In contrast, *mef2cb* single mutants failed to show the cardiac-specific phenotype observed by two independent labs in *Mef2cb* morphants [33, 34]. In our view, therefore, results from morpholino studies should be treated with caution until either replicated by clean genetic analyses or a molecular mechanism is demonstrated explaining compensatory changes that rescue mutants [61]. Loss-of-function mutations in the other *Mef2* genes are yet to be described. Taken together, these functional analyses suggest that a combination of *Mef2* genes contribute to the overall *Mef2* activity in skeletal muscle that is needed for proper myogenesis downstream of the MRF proteins and muscle growth, at least in part through effects on sarcomere assembly.

Although *Mef2*s normally act downstream of MRFs in skeletal myogenesis, once expressed *Mef2*s may also play a role in promoting MRF activity (see section 4.4). Over-expression of *Mef2cb* in zebrafish embryos leads to *myod* mRNA accumulation and slow myosin heavy chain expression in significant regions of cranial mesoderm [34, 36]. Over-expression of *Mef2ca*, on the other hand, does not induce these muscle genes, but instead appeared to dorsalize embryos, perhaps through up-regulation of BMP inhibitors such as chordin within the somite [36]. These data and others on the differential effects of splice variants (see 5.1) indicate that much remains to be learned about *Mef2* function in specific times, places and types of skeletal myogenesis.

3.4 Function of mouse *Mef2*

Loss-of-function alleles of *Mef2a*, *Mef2c* and *Mef2d* have been generated by deleting the second coding exon [14]. There is no obvious skeletal muscle phenotype in *Mef2a* and *Mef2d* mutants. Mutants in *Mef2c* are early embryonic lethal shortly after somite formation, presumed due to cardiovascular defects. Nevertheless, a defect in the earliest stages of skeletal muscle development was suggested based on loss of expression of a reporter transgene in the somites [62]. The effect of *Mef2c* has been further explored through conditional knock out studies. Using a skeletal muscle specific Cre-recombinase line active from stage E8.5 to delete a floxed *Mef2c* allele, it was found that the mice die at post-natal day 1 with severely disorganized and fragmented skeletal muscle [63]. However, skeletal muscle differentiated and formed

normal myofibers during embryogenesis, but such myofibers subsequently and rapidly deteriorated with disorganized sarcomeres. It was concluded that *Mef2c* plays a key role in the maintenance of sarcomere integrity [63].

It should be noted that in another study using a very similar approach to the conditional loss-of-function of *Mef2c* in skeletal muscle, the mice were viable and did not show perinatal lethality [64]. Moreover, both sarcomere organisation and muscle ultrastructure were grossly normal, although there was a reduction in slow muscle fibres (see 3.7), and a function for muscle *Mef2c* was also identified in normal growth and glucose metabolism. The mice in this study had a slightly different Cre line in a different genetic background, and a fuller discussion of the possible impact of these two aspects is presented in [64]. Such differing findings suggest the role of *Mef2c* may be more complex than hitherto understood, perhaps due to differing functions in several muscle-related cell types.

3.5 Potential functions in muscle-related tissues

Chick *Mef2c* is expressed early and broadly in mesoderm, suggesting it may affect development of various tissues [25]. Over-expression of zebrafish *Mef2cs* in heterologous systems may influence osteo- or chondrogenesis through Sox9/BMP [65]. After initial myogenesis, zebrafish *mef2ca* mRNA becomes localised to fibre ends, whereas *Xenopus Mef2c* has been suggested to function in early tendon cells [29, 66]. Similarly, early expression of *Mef2d* in *Xenopus* may promote dermomyotome formation in addition to specific aspects of myogenesis [67, 68]. These observations caution that potential roles of *Mef2* in muscle-related tissues could impact on muscle phenotypes observed and suggest that more research is required to define the cell autonomous roles of the *Mef2* genes in muscle development *in vivo*.

3.6 *Mef2* in muscle regeneration

Muscle regeneration in response to injury is a type of myogenesis related to, but distinct from, that occurring during development. It is dependent on satellite cells, a population of stem cells found underneath the basal lamina of muscle fibres (Zammit, this special issue). These cells generate myoblasts in post-natal skeletal muscle for both growth and for regeneration following injury, and become depleted in degenerative muscle diseases. The potential involvement of *Mef2* factors in muscle regeneration has been investigated. Loss of *Mef2a* slows regeneration ([49], but see [69] for discussion of cell autonomy). Conditional deletion of the individual *Mef2a*, *-c* or *-d* genes in mouse satellite cells *in vivo* has no effect, but the combined conditional deletion of all three genes results in a block to regeneration [69]. Analysis suggests this is due to the *Mef2* genes affecting the myoblast differentiation aspect of the regeneration process. This is the clearest demonstration to date of a function for *Mef2* genes in mammalian muscle differentiation *in vivo* and echoes the role of *Mef2* in the remodelling of *Drosophila* DLMs, a process with parallels to mammalian muscle growth and repair (see 3.2). As redundant roles for three *Mef2* genes were revealed in murine muscle regeneration, it is possible that there might be a similar situation in embryonic muscle development that has prevented phenotypes being observed in single *Mef2* gene knockouts.

3.7 Mef2 and muscle fibre character

Mef2 proteins have been implicated in the control of various aspects of muscle fibre character, either through developmental roles or by direct action in the adult fibre. Muscle fibres differ in size, contractile speed and metabolic properties based on the electrical activity imposed by the nerve that confers specific physiological characteristics to force production (reviewed in [70]). Such characteristics are frequently summarized by the term 'fibre type'. Evidence exists that Mef2 regulates both muscle fibre type and size, but how the two effects are discriminated remains unclear. On some genetic backgrounds, muscle-specific deletion of mouse *Mef2c* can reduce muscle growth and sarcomere assembly [63]. Similarly, both embryonic zebrafish and mouse postnatal muscle growth was reduced after Mef2c knockdown and, in mouse, remaining muscle had altered contractile and metabolic properties [35, 64]. Conversely, in adult zebrafish, exercise increased muscle fibre size, *mef2aa* and *mef2d* mRNAs, but decreased *mef2ca* mRNA [71]. Thus, the relationship between Mef2 and fibre character appears complex.

Analysis of adult mice in which floxed *Mef2c* or *Mef2d* alleles were recombined in skeletal muscle by Cre driven from early-muscle transgenes has implicated Mef2 activity in the regulation of murine muscle fibre type [64, 72]. *In vitro* analyses show Mef2 can cooperate with a variety of factors, including Sp1 [73] on enhancers from myoglobin (an oxidative fibre gene) and MCK (which is preferentially expressed in fast fibres). Mef2 activity was first suggested to promote the slow oxidative fibre type based on: (i) the finding that Mef2a can cooperate with activated calcineurin protein phosphatase to activate enhancer elements that are preferentially expressed in slow/oxidative soleus compared to fast EDL muscle; (ii) the ability of slow-pattern electrical activity to activate calcineurin/Nfat signaling; and (iii) the preferential expression of an artificial enhancer consisting of three Mef2 binding sites in slow soleus muscle [74-76]. Although the levels of Mef2 protein appear similar in slow and fast muscles [72], muscle-specific deletion of either *Mef2c* or *Mef2d*, but not *Mef2a*, reduced the proportion of slow fibres, whereas over-expression of a Mef2c-VP16 fusion increased slow fibre content [72]. The persistence of significant numbers of each fibre type indicates, however, that either several Mef2 proteins cooperate or that other regulators of fibre type exist; generation of muscle fibres lacking several Mef2s would be of interest.

Muscle fibre type is not determined solely by electrical activity. In chick, cell autonomous intrinsic differences between early myoblast clones have been suggested to establish fibre type pattern, which is then confirmed and refined by innervating motoneurons [77, 78]. Tests have failed to find support for the hypotheses that increase in Mef2a or Nfatc activity can drive slow myosin expression in fast myoblasts or that Mef2 binding sites operate preferentially in myotubes derived from clones that express slow myosin [79]. Moreover, in zebrafish, in which slow and fast fibres are generated before motor innervation, levels of Mef2 protein appear similar [29]. Thus, evidence is lacking of an early role of Mef2 leading to persistent change in fibre character.

4. Mechanism of Mef2 action: Transcriptional targets and networks

Having reviewed the known function of Mef2 genes in a range of aspects of muscle differentiation, we will now consider the mechanisms of Mef2 action that underpin Mef2 function: how do Mef2s do what they do? To understand the place of a transcription factor such as Mef2 in a cell differentiation program, in this Section we consider gene expression. How is *Mef2* expression regulated and what are the Mef2 target

genes, the products of which are the effector and realisor molecules that link the transcription factor with the cellular (and ultimately the animal) phenotype (see Fig. 2)? In Section 5, we will consider the Mef2 proteins and how they are modulated to produce specific outputs.

4.1 *Mef2 target genes in the context of development*

Analysis of Mef2 target genes indicates the role of Mef2 in the coordination of the gene expression programs that underpin muscle differentiation. Much initial progress in understanding the control of muscle gene expression came from single gene analysis in cultured muscle cell lines. This type of approach showed CRMs of most of the limited number of known muscle genes contained binding sites for Mef2 that are functional in cultured cells [7]. However, here we will focus on the physiological differentiation program that occurs during animal development. Initial investigations in *Drosophila* development again using the single gene approach, showed that ectopic expression of *Mef2* in the ectodermal derivatives induces the ectopic expression of a range of muscle genes, including myosin, tropomyosin, β 3-tubulin, nautilus, α PS2, muscle-blind, and muscle LIM [80-83]. *In vivo* analysis of Mef2 sites in CRMs and *in vitro* DNA-binding assays argued that a number of these genes are direct targets of Mef2, that is Mef2 binds to CRMs of the muscle gene to influence its expression [84-88]. However, the relative significance of individual targets to overall Mef2 function remained unclear.

Understanding was transformed by the application of genomic approaches, particularly Chromatin Immuno-Precipitation (ChIP) to map where Mef2 binds to genomic DNA. ChIP identified a significant number of potential Mef2 gene targets in both the mammalian C2C12 muscle cell line [43, 89] and in *Drosophila* embryos [90], the latter in conjunction with computational genome scanning for Mef2 sites. A pioneering study then used genomic ChIP in combination with gene expression profiling in *Mef2* mutant *Drosophila* embryos to identify Mef2 target genes throughout normal development [91]. A series of time-points that spanned the period of muscle development was assayed. From this analysis we highlight three significant areas:

4.1.1 *Number of Mef2 target genes*

Approximately two hundred direct target genes were identified on the basis of having Mef2 binding in the vicinity of the transcription unit and expression being affected by *Mef2* [91]. This is many more than had been anticipated from the pre-genomic era. Some of these Mef2-binding regions were shown to function as muscle CRMs. The total number of Mef2 targets could actually be double that described, because only half the genome was covered by the tiling arrays used for the ChIP, and could correspond to most muscle-specific genes.

4.1.2 *Types of Mef2 target genes*

The identified Mef2 target genes were expressed at different times during the differentiation program and have diverse functions [90, 91]. Many have roles in different aspects of terminal muscle differentiation, including muscle structure, adhesion, fusion, and neuromuscular junction assembly, which supported the widely held view of Mef2 as a regulator of the later steps of muscle differentiation [90, 91]. However, there had been prior indications of an effect of *Mef2* on muscle gene expression earlier than this [86, 92], and a striking finding from the genomic approach was that many target genes are expressed early. These genes

have roles in the specification and diversification of muscle progenitor cells. The number and diversity of Mef2 target genes expanded the view of *Mef2*, suggesting a broad role for *Mef2* in orchestrating successive steps in the muscle differentiation program *in vivo* during development.

4.1.3 *Mef2* target gene specificity

The list of Mef2 target genes identified in *Drosophila* suggests that the activity of Mef2 is regulated in both space and time. Mef2 is expressed in the entire myogenic lineage from gastrulation to the end of embryogenesis and yet some target genes are expressed early, others late, and yet others in subsets of muscle cells [91]. How does this occur?

One property of Mef2 that is regulated is its binding to chromatin. There are three temporal profiles of CRM occupancy: continuously bound by Mef2; bound early but not late; and bound late but not early [91]. Moreover, binding of Mef2 to a gene's CRM is correlated with the onset of that gene's expression, with the correlation particularly strong for the late-bound CRMs [91]. Dynamic Mef2 binding was also found during C2C12 differentiation [89]. It is not known what underpins these observations. One explanation is co-operative chromatin binding with a differentially expressed factor. Sandmann et al [91] suggest co-operative binding with the transiently expressed bHLH protein Twist as a possible explanation for transient Mef2 binding to the early group of CRMs [91]. Other possible, non-exclusive, explanations include structural changes to chromatin, as suggested for the p38 MAPK pathway in a cell culture model of muscle differentiation [42], and on modifications of Mef2 (see 5.2).

Further indications that Mef2 is not an all-or-none regulator came from another genomic approach using expression profiling of an allelic series of *Mef2* mutant embryos [93]. This revealed that target genes expressed early in muscle development require lower levels of Mef2 activity than those expressed later. The idea that levels of Mef2 activity control differential expression of muscle genes had also been suggested from expression of different levels of a *Mef2* construct in a *Mef2*-null background [82]. This showed that distinct levels of Mef2 are required in *Drosophila* for particular properties of a muscle cell.

4.2 Vertebrate genomic studies and the emerging gene expression network

Equivalent genomic studies in vertebrate embryonic development to those in *Drosophila* are challenging and have not yet been undertaken. However, genomic approaches have been applied to good effect in cultured cells. Mef2-regulated genes have been identified in satellite cell-derived myoblasts using microarrays for expression profiling [69]. Microarray analysis of genes regulated by *Mef2a*, *Mef2b*, *Mef2c* and *Mef2d* in the C2C12 muscle cell line yielded the significant finding that individual *Mef2* family members regulate specific subsets of the entire cohort of Mef2-regulated genes [94]. This was not anticipated because of the longstanding idea of functional redundancy in the vertebrate Mef2 family, which arose from the overlapping patterns of expression and lack of strong single mutant skeletal muscle phenotypes. ChIP has also been used to identify potential Mef2 target genes. In C2 muscle cells, ChIP-seq identified genes bound by Mef2d [95], whereas ChIP-exo revealed both common and distinct Mef2a genomic targets in skeletal and cardiac muscle cells [96]. These studies, although presenting an incomplete picture, make it apparent that understanding how each Mef2 regulates all its targets in a co-ordinated manner is central to understanding the network of gene expression that controls the differentiation program of each muscle cell.

4.3 Downstream of Mef2: feedback and feed forward

To reveal the organisation of the gene regulatory network, understanding of Mef2 target genes that themselves act as regulators is essential. These include: (1) other transcription factors; (2) microRNAs (Mok et al, this special issue); and (3) modulators of Mef2 activity. Here, we highlight some illustrative examples (Fig. 2).

Mef2 targets that encode transcription factors with roles in muscle development have been identified in *Drosophila* embryogenesis [91] and in C2C12 cell differentiation [43]. Each of these transcription factors will have its own cohort of target genes. These may include *Mef2* itself (see 4.4), or targets that function with Mef2 in part of a feed-forward mechanism [91]. The latter echoes a feed-forward mechanism from MyoD via Mef2 and the p38 MAPK in mammalian cultured myoblasts that produces a delay in MyoD target gene expression [42]. The intrinsic delay of such feed-forward processes can be part of timing mechanisms controlling sequential gene activation in a differentiation program (see 4.4).

MicroRNAs, which also modulate gene expression, are among the direct transcriptional targets of Mef2. Examples include miR-1 and miR-133, and the largest known mammalian microRNA cluster, the *Gtl2-Dio3* locus [49, 97, 98]. The latter is implicated in muscle regeneration. A documented example of a microRNA target that feeds back negatively on *Mef2* is miR-92b, which can interact with the 3'UTR of *Mef2* to fine-tune its expression [87].

Lastly, other Mef2 targets feed back on Mef2 to modulate its activity. These include HDAC9, a class II HDAC, which can associate with Mef2 proteins and suppress their transcriptional activity [99], and *Drosophila* Him, another inhibitor of Mef2 activity [91](Taylor MV, unpublished). How such negative feedback loops operate to achieve progress and stasis in the muscle lineage *in vivo* remains to be determined.

4.4 Closing the Loop: Regulation of Mef2 expression

In vertebrates, MRFs can induce Mef2 mRNA, protein and DNA-binding activity [5, 9, 42, 100]. The specific DNA sequence in the mouse *Mef2c* gene required for its direct activation *in vivo* by MRFs has been defined [101, 102], as have other CRMs for other regulatory inputs [103]. There is also auto-activation of Mef2 expression, and this may be direct or indirect. One indirect route is through Mef2 proteins activating the expression of MRF genes, which in turn activate Mef2 genes. Such positive feedback has been described for *myogenin* in both cell culture and developing mouse embryos, and for *Myod* in satellite cells [104-107]. A direct route to auto-activation has been suggested for mouse *Mef2c* [101], but others have not found this [102].

There are significant parallels in the transcriptional regulation of the *Drosophila Mef2* gene. It also has multiple CRMs, which indicates the capacity to integrate many regulatory inputs [108]. Notable amongst these is the bHLH transcription factor Twist, which activates *Mef2* expression [50, 109]. Twist has a major role in propelling cells down the myogenic pathway in *Drosophila* embryogenesis, and its role recalls that of the MRF family of bHLH proteins in vertebrates [110, 111]. Mef2 also acts on its own CRM, it auto-activates [112]. Other defined inputs include Tinman, which is related to the Nkx2 group of vertebrate transcription factors, and the steroid hormone ecdysone that functions in the coordination of metamorphosis [113, 114].

The cross-activation between Mef2 and the myogenic bHLH factors coupled with the observed auto-activation, in both *Drosophila* and vertebrates, points to evolutionarily conserved positive feedback gene

transcription loops as a mechanism for cell commitment. These loops can amplify and maintain the expression of these key transcription factors with the potential to maintain muscle differentiation. This is a central feature to incorporate into models of the regulatory transcriptional network that underpins muscle differentiation (Fig. 2).

4.5 Network features

Taken together, the above information indicates how the network will include both feed-forward and feed-back loops and how the activity of nodes like Mef2 in the muscle network might operate. Another aspect to incorporate into any model, as emphasised by Cunha et al [115], is the combinatorial and temporal features of the regulation of a gene at any node in the network. Initial steps to assemble this type of information have been taken. For example, Twist co-occupies 42% of all Mef2 bound CRMs in the early steps of *Drosophila* mesoderm development [116], and Lmd, a Gli-family transcription factor, modulates Mef2 transcriptional output when co-occupying CRMs [115].

In vertebrates, distinct properties of the different Mef2 and MRF family members also need to be considered. For example, there are aspects of the transcriptional inter-relationship between MRFs and Mef2s that are specific to particular members of the two families of transcription factors [117]. More generally, there are non-overlapping gene sets in the population of genes regulated by each of the four different mouse Mef2 genes, and only a small percentage of genes are co-regulated by all four [94]. Lastly, for any specific family member, relationships may not be the same in all situations. For example, Twist and Mef2 are not co-expressed at all stages of *Drosophila* muscle development. Clearly, although we can highlight key aspects of the network in muscle, much is not understood currently. Nevertheless, the prize for this substantial task of defining the myogenic network will be insights into how robustness of the transcription program is achieved and how its activity can respond to different conditions.

5. Mechanism of Mef2 action: post-transcriptional events

Multiple findings indicate that to comprehend the roles of Mef2 one must understand how its activity is regulated. Thus, Mef2 muscle target genes are expressed in both a spatially and temporally regulated manner during development (see 4.1). For example, Mef2 protein is expressed in *Drosophila* muscle progenitor cells very many hours before differentiation is underway and many target genes are expressed [118]. Although outside the scope of this review, Mef2 also functions in different cell-types to produce distinct outputs [21]. Combining these two characteristics, Mef2 may fulfil different functions in time and space within the developing and mature skeletal muscle system. Insight into how Mef2 is able to undertake its range of roles will require understanding of its post-transcriptional regulation. Here we highlight alternative splicing, protein modifications and protein interactions. Each was identified in the early years of Mef2 research, but much has been discovered since.

5.1 Alternative splicing

One way to diversify gene function is through alternative RNA splicing. Mef2 proteins across the metazoa show many small conserved regions throughout their length, in addition to the highly conserved N-

terminal MADS/Mef2 domain (Fig. 1). Furthermore, evolution has varied Mef2 gene products through alternative splicing, which appears to focus in specific regions, presumably those most forgiving of alteration, yet controlling function. For example, although *Drosophila Mef2* shows little conservation beyond the conserved N-terminal regions, the locations of exon borders and alternative splice sites are similar to those in vertebrate Mef2 genes. Two splice variants map to the region of the vertebrate alternatively spliced γ exon, despite lacking obvious sequence homology (designated exon 8 and γ' in Fig. 1) [50, 82]. In vertebrates, specific alternative splice variants in these regions are generated in muscle, but *Drosophila Mef2* isoforms have yet to reveal distinct function [82]. Even diploblasts, e.g. jellyfish and sea anemone, appear to require full length Mef2 for their mesendoderm-derived myogenesis and show good conservation to vertebrate Mef2s, with regions of alternative splicing matching a subset of those in vertebrates [119, 120]. Despite this conservation, individual species have sometimes lost domains. Downstream of the N-terminus *C. elegans Mef2* lacks most homologous regions, except for a C-terminal stretch matching the γ -exon, but it is not essential in myogenesis [121]. Such changes suggest that specific Mef2 sub-functions may only be retained in Mef2 genes of some species.

The multiplication of vertebrate Mef2 genes has permitted gene diversification. *Mef2b* genes show significantly greater divergence and lack two exons, obvious muscle-specific splice variants and several conserved domains [122]. In contrast, *Mef2a*, *-c* and *-d* genes have generally maintained alternative splicing, suggesting that each retains distinct functions in their splice variants (Fig. 1). Specific functions have been addressed in cell culture studies. Muscle-specific splicing of exon 3 occurs in *Mef2a*, *-c* and *-d* [9, 123-126]. In *Mef2d*, this seems to regulate responsiveness to PKA signaling that can control myoblast differentiation, whereas in *Mef2c* it controls responsiveness to kinases regulating the cell cycle and growth [95, 123, 127]. Splicing at other locations may modulate the efficacy of Mef2 in myogenesis by controlling its interaction with MyoD, responsiveness to signals and transcriptional activity [36, 128, 129].

Of potential clinical relevance, inclusion of exon 3 α 2 in *Mef2c* is diminished in rhabdomyosarcoma cells and replacement can reverse transformation and promote their terminal differentiation [130]. Moreover, altered Mef2 splicing may contribute to myotonic dystrophy [131]. Mechanistic understanding of Mef2 alternative splicing is rudimentary, and whether similar splice variants show common functional differences in various tissues or between genes remains unclear [67, 132]. Further studies are therefore essential to understand the regulation of alternative splicing and the functional roles of each isoform produced in muscle tissue *in vivo*.

5.2 Mef2 modification

Since the demonstration that phosphorylation of the MADS/Mef2 domain Mef2 in cultured cells could increase its DNA-binding activity [133], many different types of modification in different domains of Mef2 have been reported. These include the following illustrative examples in cultured muscle cell lines. p38 MAPK phosphorylates Mef2 at a number of sites and Thr293 phosphorylation of Mef2c is linked to enhanced transcriptional activity [134]. p38 also regulates the formation of DNA-binding Mef2/MyoD complexes and RNA PolII recruitment [42]. Mef2d is phosphorylated by PKA at Ser121 and Ser190 and this is linked to repressed transcriptional activity [135]. Transcriptional activity of Mef2D is also repressed by methylation at Lys267 [136] and by sumoylation at Lys439 in the C-terminal activation domain [137]. Another modification linked to Mef2 function is acetylation. In Mef2c this occurs at Lys4 [138] and at multiple sites in the activation

domain [139]. In both cases, modification is differentiation-dependent and DNA-binding activity is enhanced. In general, much remains unknown concerning the effects of these modifications and their significance *in vivo* during muscle development. Nevertheless, one example with intriguing *in vivo* findings is p38 MAPK, which is required for Mef2 activity and for muscle differentiation in mouse development [140]. In *Drosophila*, p38 activity in muscles regulates motor function and was shown to work through Mef2 in the regulation of life span [141]. This brief survey indicates that Mef2 proteins can be covalently modified in a variety of ways and that these modifications are a route to modulating Mef2 protein function.

5.3 Mef2 protein interactions

Shortly after its discovery it was apparent that protein interactions were significant to Mef2 function: it both dimerised and interacted with the MRFs [8, 41, 142]. Protein interactions can produce specific outcomes, and one largely unexplored aspect is whether the potentially large number of different Mef2 dimers have different functions. Most Mef2 protein interaction studies have been *in vitro* or in cell culture, and have been recently reviewed [143]. Here we highlight some examples with significance to Mef2 function in muscle.

Mef2 proteins interact with other transcription factors in addition to the MRFs. These include Smad proteins, which can bind to Mef2 in muscle cells and functionally co-operate in transcription assays [144]. The latter is dependent on p38 phosphorylation sites (see 5.2). Klf5 is a zinc finger transcription factor required for muscle regeneration *in vivo* and muscle differentiation in cell culture [145]. Klf5 directly associates with MyoD and Mef2 *in vitro*, and ChIP shows overlap with its chromatin sites and those bound by Mef2 and MyoD. The transcriptional adapter nTRIP6 can bind to Mef2c and repress target gene expression in myoblasts [146]. Intriguingly, TRIP6 can interact with Nup210 in a nuclear pore complex implicated in muscle gene expression control [147]. In the context of temporal control, the Nfix transcription factor that regulates fetal-specific muscle gene transcription binds to and enhances PKC-mediated phosphorylation of Mef2a and target gene expression [148]. In *Drosophila*, Mef2 can bind the myogenic bHLH protein Twist [149], paralleling the vertebrate MRF finding, and Twist co-occupies 42% of all Mef2-bound CRMs [116]. Mef2 can also bind two other transcriptional regulators with roles in muscle development, Sd and Vg, related to vertebrate TEAD and Vgl-2 respectively [149, 150].

Notable amongst the Mef2-interacting proteins are the class IIa HDACs. They can interact with Mef2 proteins and inhibit their activity, and over-expression can inhibit differentiation of muscle cell lines, a function linked to cytoplasmic/nuclear shuttling [151-153]. *In vivo*, class IIa HDACs suppress the formation of slow muscle fibres through repression of Mef2 activity [72]. Conversely, the acetyltransferase p300 can bind to Mef2c and thereby augment its transcriptional activity [154]. Lastly, the proline isomerase Pin1, which inhibits muscle differentiation in culture, can bind Mef2c isoforms containing the 3 α 1 exon upon phosphorylation of two Ser-Pro sites [155]. Over-expression of Pin1 decreases Mef2c stability and activity, likely through an induced conformational change.

The above examples illustrate how some Mef2 interactions with other transcriptional regulators might operate in the context of CRMs that contain cognate binding sites for each transcription factor. Others, for example Vg/Vgl-2, which has no DNA-binding domain, might require just one site, or be independent of DNA-binding. They also illustrate how protein modification and protein interaction are closely inter-related. In

order to trigger modification there must be at least a transient interaction, and some interactions may be dependent on prior protein modifications.

6. Coda: Conclusions and future directions

The family of *Mef2* genes is well-characterised and a lot is known about the roles of the encoded Mef2 transcription factors in muscle cells. However, there are significant gaps to fill in linking findings in cell culture to the *in vivo* muscle differentiation program. First, what do the different Mef2 genes do? Second, Mef2 genes produce different proteins by alternative splicing, and these proteins can undergo post-translational modifications and interact with diverse partner proteins. Understanding how these features impact on Mef2 protein activity to produce specific transcriptional outputs will be pivotal to a full understanding of Mef2 function within the muscle differentiation program. Moreover, although we have focussed on Mef2 in skeletal muscle, Mef2 has roles in other cell-types [14, 21, 156-158], and therefore, similar analyses in different tissues may illuminate Mef2 roles in muscle.

An unknown is the ancestral function of *Mef2*. As mentioned above, in some species, Mef2 is neither expressed in muscle, nor required for myogenesis [121, 159]. In these species it is possible that another MADS protein, an SRF family homologue, fulfils a Mef2-like role [160]. SRF and Mef2 homologues exist in yeast and regulate cell shape and stress-resistance [161]. As, in animals, SRF is a fundamental actin sensor [162] and muscle evolved as an extreme adaptation of the actomyosin cytoskeleton [163], modification of an actin-sensor system involving a MADS protein may have participated in the evolution of muscle. Such thinking indicates that in considering the various extant functions of Mef2 proteins, it will be helpful to identify conserved ancestral Mef2 function(s) and the evolutionary clades in which specific new roles evolved.

A core area for future work is the transcription network that underpins the muscle phenotype. The first steps to understand this on a genomic scale during development have been taken in *Drosophila*. Linking *in vivo* functional networks to the regulatory layers of chromatin and nuclear organisation will be illuminating. For example, p38 signalling to Mef2D can recruit a chromatin modifier to muscle gene CRMs [164, 165], and spatial organisation of the CRMs of muscle genes is reported to contribute to temporal regulation of expression [166]. In a similar vein, a Mef2c-containing complex has been described assembled at the nuclear pore to regulate muscle gene expression, development and maintenance [147]. Integration of these additional regulatory layers with more conventional gene expression studies will produce an in-depth understanding of the muscle differentiation program.

Acknowledgement

SMH is a Medical Research Council Scientist with Programme Grant MR/N021231/1 support. We apologise that, due to space limitations, in some areas we have had to quote previous reviews rather than the primary literature. We thank Massimo Ganassi and Yaniv Hinits for comments on the manuscript.

Figure legends

Figure 1 Alignment of Mef2 Structure and Functions.

Top row: named protein domains and their sizes. HJURP-C Holliday Junction Recognition

Protein C-terminal Domain, TAD Transactivation domain, NLS nuclear localisation sequence.

Second row: Conserved vertebrate exon structure (approximately to scale) showing alternative splices with nomenclature following Ganassi et al (2014). Vertical black lines denote exon boundaries. Grey boxes indicate alternate splice donor/acceptor sites.

Third row: conservation of domains is indicated by colour intensity (lengths not to scale). Species showing conserved regions are listed beneath: Hs *Homo sapiens*, Dr Fish *Danio rerio*, Brachi Brachiopod *Terebratalia transversa*, Ce Nematode *Caenorhabditis elegans*, Dm Fly *Drosophila melanogaster*, Pc Jellyfish *Podocoryne carnea*, Nv Sea anemone *Nematostella vectensis*.

Fourth to sixth rows: conserved exon structure and splice locations in Dm and Nv and lesser central conservation in Ce. Exon length differences are indicative, but not to scale.

Figure 2. Schematic model of Mef2 at a nexus in the network of gene expression that underpins the muscle differentiation program

1. Mef2 transcription is stimulated by the muscle bHLH proteins and by direct and indirect auto-regulatory loops (in red) and other inputs.
2. Mef2 transcripts are alternatively spliced.
3. Distinct Mef2 proteins are produced from different RNAs and different paralogous genes. They form dimers with the potential for distinct functions
4. Mef2 proteins activate a series of targets (arrows indicate the possibility of shared and distinct targets between different Mef2 proteins). The effectors include other transcription factors, microRNAs and other regulators (e.g. HDACs), which can feedback onto Mef2 through different routes (in blue). Mef2 plus these transcription factors can feed-forward (7) onto realiser genes (6).
5. The activity of Mef2 protein is modulated by modifications (X and Y), interaction with other proteins, including transcription factors and other regulators e.g. HDACs.
6. Mef2 proteins in different contexts/forms activate a range of realiser genes over space and time to produce the muscle phenotype.
7. Some realiser genes may be activated by a feed-forward mechanism.

Figure 1





Figure 2



References

1. Davis, R.L., H. Weintraub, and A.B. Lassar, *Expression of a single transfected cDNA converts fibroblasts to myoblasts*. Cell, 1987. **51**(6): p. 987-1000.
2. Weintraub, H., et al., *The myoD gene family: nodal point during specification of the muscle cell lineage*. Science, 1991. **251**(4995): p. 761-6.
3. Berkes, C.A. and S.J. Tapscott, *MyoD and the transcriptional control of myogenesis*. Semin Cell Dev Biol, 2005. **16**(4-5): p. 585-95.
4. Parmacek, M.S., et al., *A novel myogenic regulatory circuit controls slow/cardiac troponin C gene transcription in skeletal muscle*. Mol Cell Biol, 1994. **14**(3): p. 1870-85.
5. Molkenkin, J.D. and E.N. Olson, *Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors*. Proc Natl Acad Sci U S A, 1996. **93**(18): p. 9366-73.
6. Gossett, L.A., et al., *A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple muscle-specific genes*. Mol Cell Biol, 1989. **9**(11): p. 5022-33.
7. Black, B.L. and E.N. Olson, *Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins*. Annu Rev Cell Dev Biol, 1998. **14**: p. 167-96.
8. Pollock, R. and R. Treisman, *Human SRF-related proteins: DNA-binding properties and potential regulatory targets*. Genes Devel., 1991. **5**: p. 2327-2341.
9. Yu, Y.T., et al., *Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors*. Genes Dev, 1992. **6**(9): p. 1783-98.
10. Schwarz-Sommer, Z., et al., *Genetic Control of Flower Development by Homeotic Genes in Antirrhinum majus*. Science, 1990. **250**(4983): p. 931-6.
11. Shore, P. and A.D. Sharrocks, *The MADS-box family of transcription factors*. Eur J Biochem, 1995. **229**(1): p. 1-13.
12. Mohun, T.J., et al., *Expression of genes encoding the transcription factor SRF during early development of Xenopus laevis: identification of a CArG box-binding activity as SRF*. EMBO J, 1991. **10**(4): p. 933-40.
13. Braun, T. and M. Gautel, *Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis*. Nat Rev Mol Cell Biol, 2011. **12**(6): p. 349-61.
14. Desjardins, C.A. and F.J. Naya, *The Function of the MEF2 Family of Transcription Factors in Cardiac Development, Cardiogenomics, and Direct Reprogramming*. J Cardiovasc Dev Dis, 2016. **3**(3).
15. Nguyen, T., J. Wang, and R.A. Schulz, *Mutations within the conserved MADS box of the D-MEF2 muscle differentiation factor result in a loss of DNA binding ability and lethality in Drosophila*. Differentiation, 2002. **70**(8): p. 438-46.
16. Molkenkin, J.D., et al., *Mutational analysis of the DNA binding, dimerization, and transcriptional activation domains of MEF2C*. Mol Cell Biol, 1996. **16**(6): p. 2627-36.
17. Meierhans, D., M. Sieber, and R.K. Allemann, *High affinity binding of MEF-2C correlates with DNA bending*. Nucleic Acids Res, 1997. **25**(22): p. 4537-44.
18. Santelli, E. and T.J. Richmond, *Crystal structure of MEF2A core bound to DNA at 1.5 Å resolution*. J Mol Biol, 2000. **297**(2): p. 437-49.
19. Huang, K., et al., *Solution structure of the MEF2A-DNA complex: structural basis for the modulation of DNA bending and specificity by MADS-box transcription factors*. EMBO J, 2000. **19**(11): p. 2615-28.
20. Wu, Y., et al., *Structure of the MADS-box/MEF2 domain of MEF2A bound to DNA and its implication for myocardin recruitment*. J Mol Biol, 2010. **397**(2): p. 520-33.
21. Potthoff, M.J. and E.N. Olson, *MEF2: a central regulator of diverse developmental programs*. Development, 2007. **134**(23): p. 4131-40.
22. Taylor, M.V., *Muscle development. Making Drosophila muscle*. Curr Biol, 1995. **5**(7): p. 740-2.
23. Edmondson, D.G., et al., *Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis*. Development, 1994. **120**(5): p. 1251-1263.
24. Diez-Roux, G., et al., *A high-resolution anatomical atlas of the transcriptome in the mouse embryo*. PLoS Biol, 2011. **9**(1): p. e1000582.

25. Berti, F., et al., *Time course and side-by-side analysis of mesodermal, pre-myogenic, myogenic and differentiated cell markers in the chicken model for skeletal muscle formation*. J Anat, 2015. **227**(3): p. 361-82.
26. Buchberger, A. and H.H. Arnold, *The MADS domain containing transcription factor cMef2a is expressed in heart and skeletal muscle during embryonic chick development*. Dev Genes Evol, 1999. **209**(6): p. 376-81.
27. Ticho, B.S., et al., *Three zebrafish MEF2 genes delineate somitic and cardiac muscle development in wild-type and mutant embryos*. Mechanisms of Development, 1996. **59**(2): p. 205-218.
28. Vogel, A.M. and T. Gerster, *A zebrafish homolog of the serum response factor gene is highly expressed in differentiating embryonic myocytes*. Mech Dev, 1999. **81**(1-2): p. 217-21.
29. Hinitz, Y. and S.M. Hughes, *Mef2s are required for thick filament formation in nascent muscle fibres*. Development, 2007. **134**(13): p. 2511-9.
30. Thisse, B., et al., *Spatial and temporal expression of the zebrafish genome by large-scale in situ hybridization screening*. Methods Cell Biol, 2004. **77**: p. 505-19.
31. Wang, Y., et al., *Myocyte-specific enhancer factor 2A is essential for zebrafish posterior somite development*. Mech Dev, 2006. **123**(10): p. 783-91.
32. Lv, F., et al., *Generation of a mef2aa:EGFP transgenic zebrafish line that expresses EGFP in muscle cells*. Fish Physiol Biochem, 2017. **43**(1): p. 287-294.
33. Lazic, S. and I.C. Scott, *Mef2cb regulates late myocardial cell addition from a second heart field-like population of progenitors in zebrafish*. Dev Biol, 2011. **354**(1): p. 123-33.
34. Hinitz, Y., et al., *Zebrafish Mef2ca and Mef2cb are essential for both first and second heart field cardiomyocyte differentiation*. Dev Biol, 2012. **369**(2): p. 199-210.
35. Yogeve, O., et al., *elF4EBP3L acts as a gatekeeper of TORC1 in activity-dependent muscle growth by specifically regulating Mef2ca translational initiation*. PLoS Biol, 2013. **11**(10): p. e1001679.
36. Ganassi, M., et al., *Distinct functions of alternatively spliced isoforms encoded by zebrafish mef2ca and mef2cb*. Biochim Biophys Acta, 2014. **1839**(7): p. 559-70.
37. Devoto, S.H., et al., *Identification of separate slow and fast muscle precursor cells in vivo, prior to somite formation*. Development, 1996. **122**: p. 3371-3380.
38. Patterson, S.E., N.C. Bird, and S.H. Devoto, *BMP regulation of myogenesis in zebrafish*. Dev Dyn, 2010. **239**(3): p. 806-17.
39. Windner, S.E., et al., *Fss/Tbx6 is required for central dermomyotome cell fate in zebrafish*. Biol Open, 2012. **1**(8): p. 806-14.
40. Windner, S.E., et al., *Tbx6, Mesp-b and Ripply1 regulate the onset of skeletal myogenesis in zebrafish*. Development, 2015. **142**(6): p. 1159-68.
41. Molkenstein, J.D., et al., *Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins*. Cell, 1995. **83**(7): p. 1125-36.
42. Penn, B.H., et al., *A MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation*. Genes Dev, 2004. **18**(19): p. 2348-53.
43. Blais, A., et al., *An initial blueprint for myogenic differentiation*. Genes Dev, 2005. **19**(5): p. 553-69.
44. Cao, Y., et al., *Genome-wide MyoD binding in skeletal muscle cells: a potential for broad cellular reprogramming*. Dev Cell, 2010. **18**(4): p. 662-74.
45. Kwon, A.T., et al., *Validation of skeletal muscle cis-regulatory module predictions reveals nucleotide composition bias in functional enhancers*. PLoS Comput Biol, 2011. **7**(12): p. e1002256.
46. Davis, R.L., et al., *The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation*. Cell, 1990. **60**(5): p. 733-46.
47. Brennan, T.J., T. Chakraborty, and E.N. Olson, *Mutagenesis of the myogenin basic region identifies an ancient protein motif critical for activation of myogenesis*. Proc Natl Acad Sci U S A, 1991. **88**(13): p. 5675-9.
48. Ornatsky, O.I., J.J. Andreucci, and J.C. McDermott, *A dominant-negative form of transcription factor MEF2 inhibits myogenesis*. J Biol Chem, 1997. **272**(52): p. 33271-8.
49. Snyder, C.M., et al., *MEF2A regulates the Gtl2-Dio3 microRNA mega-cluster to modulate WNT signaling in skeletal muscle regeneration*. Development, 2013. **140**(1): p. 31-42.

50. Taylor, M.V., et al., *Drosophila MEF2 is regulated by twist and is expressed in both the primordia and differentiated cells of the embryonic somatic, visceral and heart musculature*. Mech Dev, 1995. **50**(1): p. 29-41.
51. Bour, B.A., et al., *Drosophila MEF2, a transcription factor that is essential for myogenesis*. Genes Dev, 1995. **9**(6): p. 730-41.
52. Lilly, B., et al., *Requirement of MADS domain transcription factor D-MEF2 for muscle formation in Drosophila*. Science, 1995. **267**(5198): p. 688-93.
53. Bernstein, S.I., P.T. O'Donnell, and R.M. Cripps, *Molecular genetic analysis of muscle development, structure, and function in Drosophila*. Int Rev Cytol, 1993. **143**: p. 63-152.
54. Bate, M., *The mesoderm and its derivatives*, in *The Development of Drosophila melanogaster*, M. Bate, Martinez-Arias, A., Editor. 1993, Cold Spring Harbor Press: New York. p. 1013-1090.
55. Taylor, M.V., *Comparison of Muscle Development in Drosophila and Vertebrates*, in *Muscle Development in Drosophila*, H. Slink, Editor. 2006, Landes Bioscience: Austin, TX. p. 169-203.
56. Maqbool, T. and K. Jagla, *Genetic control of muscle development: learning from Drosophila*. J Muscle Res Cell Motil, 2007. **28**(7-8): p. 397-407.
57. Ranganayakulu, G., et al., *A series of mutations in the D-MEF2 transcription factor reveal multiple functions in larval and adult myogenesis in Drosophila*. Dev Biol, 1995. **171**(1): p. 169-81.
58. Cripps, R.M. and E.N. Olson, *Twist is required for muscle template splitting during adult Drosophila myogenesis*. Dev Biol, 1998. **203**(1): p. 106-15.
59. Soler, C., J. Han, and M.V. Taylor, *The conserved transcription factor Mef2 has multiple roles in adult Drosophila musculature formation*. Development, 2012. **139**(7): p. 1270-5.
60. Bryantsev, A.L., et al., *Differential requirements for Myocyte Enhancer Factor-2 during adult myogenesis in Drosophila*. Dev Biol, 2012. **361**(2): p. 191-207.
61. Stainier, D.Y.R., et al., *Guidelines for morpholino use in zebrafish*. PLoS Genet, 2017. **13**(10): p. e1007000.
62. Lin, Q., et al., *Requirement of the MADS-box transcription factor MEF2C for vascular development*. Development, 1998. **125**(22): p. 4565-74.
63. Potthoff, M.J., et al., *Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c*. Mol Cell Biol, 2007. **27**(23): p. 8143-51.
64. Anderson, C.M., et al., *Myocyte enhancer factor 2C function in skeletal muscle is required for normal growth and glucose metabolism in mice*. Skelet Muscle, 2015. **5**: p. 7.
65. Marques, C.L., M.L. Cancela, and V. Laize, *Transcriptional regulation of gilthead seabream bone morphogenetic protein (BMP) 2 gene by bone- and cartilage-related transcription factors*. Gene, 2016. **576**(1 Pt 2): p. 229-36.
66. della Gaspera, B., et al., *The Xenopus MEF2 gene family: evidence of a role for XMEF2C in larval tendon development*. Dev Biol, 2009. **328**(2): p. 392-402.
67. Della Gaspera, B., et al., *Mef2d acts upstream of muscle identity genes and couples lateral myogenesis to dermomyotome formation in Xenopus laevis*. PLoS One, 2012. **7**(12): p. e52359.
68. Kolpakova, A., et al., *Transcriptional regulation of mesoderm genes by MEF2D during early Xenopus development*. PLoS One, 2013. **8**(7): p. e69693.
69. Liu, N., et al., *Requirement of MEF2A, C, and D for skeletal muscle regeneration*. Proc Natl Acad Sci U S A, 2014. **111**(11): p. 4109-14.
70. Schiaffino, S. and C. Reggiani, *Fiber types in mammalian skeletal muscles*. Physiol Rev, 2011. **91**(4): p. 1447-531.
71. Palstra, A.P., et al., *Swimming-induced exercise promotes hypertrophy and vascularization of fast skeletal muscle fibres and activation of myogenic and angiogenic transcriptional programs in adult zebrafish*. BMC Genomics, 2014. **15**: p. 1136.
72. Potthoff, M.J., et al., *Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers*. J Clin Invest, 2007. **117**(9): p. 2459-67.
73. Grayson, J., R. Bassel-Duby, and R.S. Williams, *Collaborative interactions between MEF-2 and Sp1 in muscle-specific gene regulation*. J Cell Biochem, 1998. **70**(3): p. 366-75.
74. Chin, E., et al., *A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type*. Genes Dev., 1998. **12**(16): p. 2499-2509.

75. Wu, H., et al., *MEF2 responds to multiple calcium-regulated signals in the control of skeletal muscle fiber type*. *Embo J*, 2000. **19**(9): p. 1963-73.
76. Wu, H., et al., *Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway*. *EMBO J*, 2001. **20**(22): p. 6414-23.
77. Miller, J.B. and F.E. Stockdale, *Developmental origins of skeletal muscle fibres: clonal analysis of myogenic cell lineages based on expression of fast and slow myosin heavy chains*. *Proceedings of the National Academy of Sciences USA*, 1986. **83**(JUN): p. 3860-3864.
78. Hughes, S.M. and P.C. Salinas, *Control of muscle fibre and motoneuron diversification*. *Curr Opin Neurobiol*, 1999. **9**(1): p. 54-64.
79. Theobald, J. and J.X. DiMario, *Lineage-based primary muscle fiber type diversification independent of MEF2 and NFAT in chick embryos*. *J Muscle Res Cell Motil*, 2011. **31**(5-6): p. 369-81.
80. Lin, M.H., et al., *Ectopic expression of MEF2 in the epidermis induces epidermal expression of muscle genes and abnormal muscle development in Drosophila*. *Dev Biol*, 1997. **182**(2): p. 240-55.
81. Artero, R., et al., *The muscleblind gene participates in the organization of Z-bands and epidermal attachments of Drosophila muscles and is regulated by Dmef2*. *Dev Biol*, 1998. **195**(2): p. 131-43.
82. Gunthorpe, D., K.E. Beatty, and M.V. Taylor, *Different levels, but not different isoforms, of the Drosophila transcription factor DMEF2 affect distinct aspects of muscle differentiation*. *Dev Biol*, 1999. **215**(1): p. 130-45.
83. Stronach, B.E., et al., *Muscle LIM proteins are associated with muscle sarcomeres and require dMEF2 for their expression during Drosophila myogenesis*. *Mol Biol Cell*, 1999. **10**(7): p. 2329-42.
84. Lin, M.H., et al., *Myocyte-specific enhancer factor 2 acts cooperatively with a muscle activator region to regulate Drosophila tropomyosin gene muscle expression*. *Proc Natl Acad Sci U S A*, 1996. **93**(10): p. 4623-8.
85. Damm, C., et al., *Independent regulatory elements in the upstream region of the Drosophila beta 3 tubulin gene (beta Tub60D) guide expression in the dorsal vessel and the somatic muscles*. *Dev Biol*, 1998. **199**(1): p. 138-49.
86. Kelly, K.K., S.M. Meadows, and R.M. Cripps, *Drosophila MEF2 is a direct regulator of Actin57B transcription in cardiac, skeletal, and visceral muscle lineages*. *Mech Dev*, 2002. **110**(1-2): p. 39-50.
87. Chen, Z., et al., *miR-92b regulates Mef2 levels through a negative-feedback circuit during Drosophila muscle development*. *Development*, 2012. **139**(19): p. 3543-52.
88. Brunetti, T.M., B.J. Fremin, and R.M. Cripps, *Identification of singles bar as a direct transcriptional target of Drosophila Myocyte enhancer factor-2 and a regulator of adult myoblast fusion*. *Dev Biol*, 2015. **401**(2): p. 299-309.
89. Paris, J., et al., *Identification of MEF2-regulated genes during muscle differentiation*. *Physiol Genomics*, 2004. **20**(1): p. 143-51.
90. Junion, G., et al., *Mapping Dmef2-binding regulatory modules by using a ChIP-enriched in silico targets approach*. *Proc Natl Acad Sci U S A*, 2005. **102**(51): p. 18479-84.
91. Sandmann, T., et al., *A temporal map of transcription factor activity: mef2 directly regulates target genes at all stages of muscle development*. *Dev Cell*, 2006. **10**(6): p. 797-807.
92. Taylor, M.V., *A novel Drosophila, mef2-regulated muscle gene isolated in a subtractive hybridization-based molecular screen using small amounts of zygotic mutant RNA*. *Dev Biol*, 2000. **220**(1): p. 37-52.
93. Elgar, S.J., J. Han, and M.V. Taylor, *mef2 activity levels differentially affect gene expression during Drosophila muscle development*. *Proc Natl Acad Sci U S A*, 2008. **105**(3): p. 918-23.
94. Estrella, N.L., et al., *MEF2 transcription factors regulate distinct gene programs in mammalian skeletal muscle differentiation*. *J Biol Chem*, 2015. **290**(2): p. 1256-68.
95. Sebastian, S., et al., *Tissue-specific splicing of a ubiquitously expressed transcription factor is essential for muscle differentiation*. *Genes Dev*, 2013. **27**(11): p. 1247-59.
96. Wales, S., et al., *Global MEF2 target gene analysis in cardiac and skeletal muscle reveals novel regulation of DUSP6 by p38MAPK-MEF2 signaling*. *Nucleic Acids Res*, 2014. **42**(18): p. 11349-62.
97. Sokol, N.S. and V. Ambros, *Mesodermally expressed Drosophila microRNA-1 is regulated by Twist and is required in muscles during larval growth*. *Genes Dev*, 2005. **19**(19): p. 2343-54.
98. Liu, N., et al., *An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133*. *Proc Natl Acad Sci U S A*, 2007. **104**(52): p. 20844-9.

99. Haberland, M., et al., *Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation*. Mol Cell Biol, 2007. **27**(2): p. 518-25.
100. Lassar, A.B., et al., *Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo*. Cell, 1991. **66**(2): p. 305-15.
101. Wang, D.Z., et al., *The Mef2c gene is a direct transcriptional target of myogenic bHLH and MEF2 proteins during skeletal muscle development*. Development, 2001. **128**(22): p. 4623-33.
102. Dodou, E., S.M. Xu, and B.L. Black, *mef2c is activated directly by myogenic basic helix-loop-helix proteins during skeletal muscle development in vivo*. Mech Dev, 2003. **120**(9): p. 1021-32.
103. Agarwal, P., et al., *The MADS box transcription factor MEF2C regulates melanocyte development and is a direct transcriptional target and partner of SOX10*. Development, 2011. **138**(12): p. 2555-65.
104. Edmondson, D.G., et al., *Analysis of the myogenin promoter reveals an indirect pathway for positive autoregulation mediated by the muscle-specific enhancer factor MEF-2*. Mol Cell Biol, 1992. **12**(9): p. 3665-77.
105. Yee, S.P. and P.W. Rigby, *The regulation of myogenin gene expression during the embryonic development of the mouse*. Genes Dev, 1993. **7**(7A): p. 1277-89.
106. Cheng, T.C., et al., *Separable regulatory elements governing myogenin transcription in mouse embryogenesis*. Science, 1993. **261**(5118): p. 215-8.
107. Mokalled, M.H., et al., *MASTR directs MyoD-dependent satellite cell differentiation during skeletal muscle regeneration*. Genes Dev, 2012. **26**(2): p. 190-202.
108. Nguyen, H.T. and X. Xu, *Drosophila mef2 expression during mesoderm development is controlled by a complex array of cis-acting regulatory modules*. Dev Biol, 1998. **204**(2): p. 550-66.
109. Cripps, R.M., et al., *The myogenic regulatory gene Mef2 is a direct target for transcriptional activation by Twist during Drosophila myogenesis*. Genes Dev, 1998. **12**(3): p. 422-34.
110. Baylies, M.K. and M. Bate, *twist: A myogenic switch in Drosophila*. Science, 1996. **272**(5267): p. 1481-1484.
111. Taylor, M.V., *A myogenic switch*. Muscle development. Curr Biol, 1996. **6**(8): p. 924-6.
112. Cripps, R.M., T.L. Lovato, and E.N. Olson, *Positive autoregulation of the Myocyte enhancer factor-2 myogenic control gene during somatic muscle development in Drosophila*. Dev Biol, 2004. **267**(2): p. 536-47.
113. Gajewski, K., et al., *Combinatorial control of Drosophila mef2 gene expression in cardiac and somatic muscle cell lineages*. Dev Genes Evol, 1998. **208**(7): p. 382-92.
114. Lovato, T.L., A.R. Benjamin, and R.M. Cripps, *Transcription of Myocyte enhancer factor-2 in adult Drosophila myoblasts is induced by the steroid hormone ecdysone*. Dev Biol, 2005. **288**(2): p. 612-21.
115. Cunha, P.M., et al., *Combinatorial binding leads to diverse regulatory responses: Lmd is a tissue-specific modulator of Mef2 activity*. PLoS Genet, 2010. **6**(7): p. e1001014.
116. Sandmann, T., et al., *A core transcriptional network for early mesoderm development in Drosophila melanogaster*. Genes Dev, 2007. **21**(4): p. 436-49.
117. Ridgeway, A.G., S. Wilton, and I.S. Skerjanc, *Myocyte enhancer factor 2C and myogenin up-regulate each other's expression and induce the development of skeletal muscle in P19 cells*. J Biol Chem, 2000. **275**(1): p. 41-6.
118. Soler, C. and M.V. Taylor, *The Him gene inhibits the development of Drosophila flight muscles during metamorphosis*. Mech Dev, 2009. **126**(7): p. 595-603.
119. Genikhovich, G. and U. Technau, *Complex functions of Mef2 splice variants in the differentiation of endoderm and of a neuronal cell type in a sea anemone*. Development, 2011. **138**(22): p. 4911-9.
120. Spring, J., et al., *Conservation of Brachyury, Mef2, and Snail in the myogenic lineage of jellyfish: a connection to the mesoderm of bilateria*. Dev Biol, 2002. **244**(2): p. 372-84.
121. Dichoso, D., et al., *The MADS-Box factor CeMEF2 is not essential for Caenorhabditis elegans myogenesis and development*. Dev Biol, 2000. **223**(2): p. 431-40.
122. Molkenstin, J.D., et al., *MEF2B is a potent transactivator expressed in early myogenic lineages*. Mol Cell Biol, 1996. **16**(7): p. 3814-24.

123. Baruffaldi, F., et al., *Dynamic Phosphorylation of the Myocyte Enhancer Factor 2 α 1 Splice Variant Promotes Skeletal Muscle Regeneration and Hypertrophy*. *Stem Cells*, 2017. **35**(3): p. 725-738.
124. Breitbart, R.E., et al., *A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage*. *Development*, 1993. **118**(4): p. 1095-106.
125. Infantino, V., et al., *MEF2C exon alpha: role in gene activation and differentiation*. *Gene*, 2013. **531**(2): p. 355-62.
126. Martin, J.F., et al., *A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing*. *Mol Cell Biol*, 1994. **14**(3): p. 1647-56.
127. Badodi, S., et al., *Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition*. *Cell Cycle*, 2015. **14**(10): p. 1517-28.
128. Zhu, B. and T. Gulick, *Phosphorylation and alternative pre-mRNA splicing converge to regulate myocyte enhancer factor 2C activity*. *Mol Cell Biol*, 2004. **24**(18): p. 8264-75.
129. Zhu, B., B. Ramachandran, and T. Gulick, *Alternative pre-mRNA splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain*. *J Biol Chem*, 2005. **280**(31): p. 28749-60.
130. Zhang, M., B. Zhu, and J. Davie, *Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells*. *J Biol Chem*, 2015. **290**(1): p. 310-24.
131. Bachinski, L.L., et al., *Altered MEF2 isoforms in myotonic dystrophy and other neuromuscular disorders*. *Muscle Nerve*, 2010. **42**(6): p. 856-63.
132. Sekiyama, Y., H. Suzuki, and T. Tsukahara, *Functional gene expression analysis of tissue-specific isoforms of Mef2c*. *Cell Mol Neurobiol*, 2012. **32**(1): p. 129-39.
133. Molkentin, J.D., L. Li, and E.N. Olson, *Phosphorylation of the MADS-Box transcription factor MEF2C enhances its DNA binding activity*. *J Biol Chem*, 1996. **271**(29): p. 17199-204.
134. Wu, Z., et al., *p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps*. *Mol Cell Biol*, 2000. **20**(11): p. 3951-64.
135. Du, M., et al., *Protein kinase A represses skeletal myogenesis by targeting myocyte enhancer factor 2D*. *Mol Cell Biol*, 2008. **28**(9): p. 2952-70.
136. Choi, J., et al., *Modulation of lysine methylation in myocyte enhancer factor 2 during skeletal muscle cell differentiation*. *Nucleic Acids Res*, 2014. **42**(1): p. 224-34.
137. Gregoire, S. and X.J. Yang, *Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors*. *Mol Cell Biol*, 2005. **25**(6): p. 2273-87.
138. Angelelli, C., et al., *Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells*. *Nucleic Acids Res*, 2008. **36**(3): p. 915-28.
139. Ma, K., et al., *Myocyte enhancer factor 2 acetylation by p300 enhances its DNA binding activity, transcriptional activity, and myogenic differentiation*. *Mol Cell Biol*, 2005. **25**(9): p. 3575-82.
140. de Angelis, L., et al., *Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway*. *Dev Biol*, 2005. **283**(1): p. 171-9.
141. Vrailas-Mortimer, A., et al., *A muscle-specific p38 MAPK/Mef2/MnSOD pathway regulates stress, motor function, and life span in Drosophila*. *Dev Cell*, 2011. **21**(4): p. 783-95.
142. Ornatsky, O.I. and J.C. McDermott, *MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells*. *J Biol Chem*, 1996. **271**(40): p. 24927-33.
143. Dong, C., et al., *Myocyte enhancer factor 2C and its directly-interacting proteins: A review*. *Prog Biophys Mol Biol*, 2017. **126**: p. 22-30.
144. Quinn, Z.A., et al., *Smad proteins function as co-modulators for MEF2 transcriptional regulatory proteins*. *Nucleic Acids Res*, 2001. **29**(3): p. 732-42.
145. Hayashi, S., et al., *Klf5 regulates muscle differentiation by directly targeting muscle-specific genes in cooperation with MyoD in mice*. *Elife*, 2016. **5**.
146. Kemler, D., et al., *The LIM domain protein nTRIP6 acts as a co-repressor for the transcription factor MEF2C in myoblasts*. *Sci Rep*, 2016. **6**: p. 27746.
147. Raices, M., et al., *Nuclear Pores Regulate Muscle Development and Maintenance by Assembling a Localized Mef2C Complex*. *Dev Cell*, 2017. **41**(5): p. 540-554 e7.

148. Messina, G., et al., *Nfix regulates fetal-specific transcription in developing skeletal muscle*. Cell, 2010. **140**(4): p. 554-66.
149. Bernard, F., et al., *Integration of differentiation signals during indirect flight muscle formation by a novel enhancer of Drosophila vestigial gene*. Dev Biol, 2009. **332**(2): p. 258-72.
150. Deng, H., et al., *Alternative requirements for Vestigial, Scalloped, and Dmef2 during muscle differentiation in Drosophila melanogaster*. Mol Biol Cell, 2009. **20**(1): p. 256-69.
151. Lu, J., et al., *Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases*. Mol Cell, 2000. **6**(2): p. 233-44.
152. McKinsey, T.A., et al., *Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation*. Nature, 2000. **408**(6808): p. 106-11.
153. Miska, E.A., et al., *Differential localization of HDAC4 orchestrates muscle differentiation*. Nucleic Acids Res, 2001. **29**(16): p. 3439-47.
154. Sartorelli, V., et al., *Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C*. Mol Cell Biol, 1997. **17**(2): p. 1010-26.
155. Magli, A., et al., *Proline isomerase Pin1 represses terminal differentiation and myocyte enhancer factor 2C function in skeletal muscle cells*. J Biol Chem, 2010. **285**(45): p. 34518-27.
156. Rocha, H., et al., *MEF2C haploinsufficiency syndrome: Report of a new MEF2C mutation and review*. Eur J Med Genet, 2016. **59**(9): p. 478-82.
157. Clark, R.I., et al., *MEF2 is an in vivo immune-metabolic switch*. Cell, 2013. **155**(2): p. 435-47.
158. Blanchard, F.J., et al., *The transcription factor Mef2 is required for normal circadian behavior in Drosophila*. J Neurosci, 2010. **30**(17): p. 5855-65.
159. Andrikou, C., et al., *Myogenesis in the sea urchin embryo: the molecular fingerprint of the myoblast precursors*. Evodevo, 2013. **4**(1): p. 33.
160. Fukushige, T., et al., *Defining the transcriptional redundancy of early bodywall muscle development in C. elegans: evidence for a unified theory of animal muscle development*. Genes Dev, 2006. **20**(24): p. 3395-406.
161. Messenguy, F. and E. Dubois, *Role of MADS box proteins and their cofactors in combinatorial control of gene expression and cell development*. Gene, 2003. **316**: p. 1-21.
162. Posern, G. and R. Treisman, *Actin' together: serum response factor, its cofactors and the link to signal transduction*. Trends Cell Biol, 2006. **16**(11): p. 588-96.
163. Leclere, L. and E. Rottinger, *Diversity of Cnidarian Muscles: Function, Anatomy, Development and Regeneration*. Front Cell Dev Biol, 2016. **4**: p. 157.
164. Rampalli, S., et al., *p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation*. Nat Struct Mol Biol, 2007. **14**(12): p. 1150-6.
165. Aziz, A., Q.C. Liu, and F.J. Dilworth, *Regulating a master regulator: establishing tissue-specific gene expression in skeletal muscle*. Epigenetics, 2010. **5**(8): p. 691-5.
166. Harada, A., et al., *Spatial re-organization of myogenic regulatory sequences temporally controls gene expression*. Nucleic Acids Res, 2015. **43**(4): p. 2008-21.